1. Academic Validation
  2. Wen-Shen-Tong-Luo-Zhi-Tong Decoction alleviates bone loss in aged mice by suppressing LONP1-mediated macrophage senescence

Wen-Shen-Tong-Luo-Zhi-Tong Decoction alleviates bone loss in aged mice by suppressing LONP1-mediated macrophage senescence

  • Pharm Biol. 2025 Dec;63(1):524-548. doi: 10.1080/13880209.2025.2537125.
Qinfeng Zhou 1 2 3 Kaixuan Wang 4 Cong Wang 1 Xiaoxian Sun 1 5 Lining Wang 1 4 5 Jie Sun 1 Yalan Pan 1 5 Muzhe Li 1 2 Zitong Zhao 1 4 Shijie Zhou 1 2 Qing Wang 6 Yafeng Zhang 5 Yong Ma 1 2 5 7 Yang Guo 1 5
Affiliations

Affiliations

  • 1 Laboratory of New Techniques of Restoration & Reconstruction of Orthopedics and Traumatology, Nanjing University of Chinese Medicine, Nanjing, China.
  • 2 Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
  • 3 Department of Laboratory Medicine, Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, China.
  • 4 School of Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
  • 5 Jiangsu CM Clinical Innovation Center of Degenerative Bone & Joint Disease, Wuxi TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Wuxi, China.
  • 6 TCM Nursing Intervention Key Laboratory of Chronic Disease, Nanjing University of Chinese Medicine, Nanjing, China.
  • 7 Yancheng TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Yancheng, China.
Abstract

Context: Aging leads to senile osteoporosis (SOP), marked by bone loss and increased fracture risk. Macrophages, as active immune cells in bone tissue, play an important role in osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) during aging. Wen-Shen-Tong-Luo-Zhi-Tong Decoction (WSTLZTD), a traditional Chinese herbal formula, has been clinically validated for its efficacy in treating SOP. However, the specific mechanisms by which WSTLZTD exerts its anti-SOP effects-particularly through modulating macrophage senescence-remain unclear.

Objective: The study aims to elucidate the role of WSTLZTD in macrophage senescence and SOP.

Materials and methods: Aged mice received low, medium, high-dose WSTLZTD. Bone loss was evaluated via micro-computed tomography, hematoxylin and eosin staining and osteocalcin, tartrate-resistant Acid Phosphatase marker analysis. Macrophage senescence detection (β-galactosidase staining, p16, p21) and molecular mechanisms by Western blot, immunohistochemistry, immunofluorescence method were investigated. Macrophage-conditioned medium's effects on BMSC osteogenesis and mitochondrial function were assessed through Alkaline Phosphatase, Alizarin Red S staining, Reactive Oxygen Species and JC-1 mitochondrial membrane potential (ΔΨm) assays.

Results: In vivo experiments demonstrated that WSTLZTD effectively ameliorated macrophage senescence and osteoporosis in naturally aged mice. Mechanistically, high-dose WSTLZTD attenuated senescence in bone marrow-derived macrophages by mediating LONP1, concurrently suppressing the Cyclic GMP-AMP Synthase (cGAS)/STING signaling pathway in BMSCs, thereby enhancing osteogenic differentiation of BMSCs. In vitro studies further confirmed that WSTLZTD-containing serum attenuated the senescent phenotype of macrophages. Notably, the LONP1 inhibitor, LONP1-IN-2, was found to diminish the anti-senescence effects of WSTLZTD on macrophages and BMSC osteogenesis.

Discussion and conclusion: WSTLZTD potentially modulate macrophage senescence via LONP1, which subsequently suppresses the activation of the cGAS/STING pathway in BMSCs, ultimately promoting their osteogenic differentiation and ameliorating osteoporosis.

Keywords

BMSC osteogenesis; LONP1; Wen-Shen-Tong-Luo-Zhi-Tong Decoction; cGAS/STING; macrophage senescence.

Figures
Products